The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Carcinoma, Transitional Cell

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Carcinoma, Transitional Cell


Psychiatry related information on Carcinoma, Transitional Cell


High impact information on Carcinoma, Transitional Cell


Chemical compound and disease context of Carcinoma, Transitional Cell


Biological context of Carcinoma, Transitional Cell


Anatomical context of Carcinoma, Transitional Cell


Gene context of Carcinoma, Transitional Cell


Analytical, diagnostic and therapeutic context of Carcinoma, Transitional Cell


  1. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. Lamm, D.L., Blumenstein, B.A., Crawford, E.D., Montie, J.E., Scardino, P., Grossman, H.B., Stanisic, T.H., Smith, J.A., Sullivan, J., Sarosdy, M.F. N. Engl. J. Med. (1991) [Pubmed]
  2. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. Gonzalez-Zulueta, M., Shibata, A., Ohneseit, P.F., Spruck, C.H., Busch, C., Shamaa, M., El-Baz, M., Nichols, P.W., Gonzalgo, M.L., Elbaz M [corrected to El-Baz, M. J. Natl. Cancer Inst. (1995) [Pubmed]
  3. Miliary tuberculosis secondary to transurethral bacillus Calmette-Guérin administration for superficial transitional cell carcinoma of the bladder. Skoutelis, A., Melekos, M.D., Bassaris, H.J. J. Natl. Cancer Inst. (1990) [Pubmed]
  4. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Summerhayes, I.C., Lampidis, T.J., Bernal, S.D., Nadakavukaren, J.J., Nadakavukaren, K.K., Shepherd, E.L., Chen, L.B. Proc. Natl. Acad. Sci. U.S.A. (1982) [Pubmed]
  5. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. Dalbagni, G., Russo, P., Sheinfeld, J., Mazumdar, M., Tong, W., Rabbani, F., Donat, M.S., Herr, H.W., Sogani, P., dePalma, D., Bajorin, D. J. Clin. Oncol. (2002) [Pubmed]
  6. Experience with bacillus Calmette-Guérin in patients with superficial bladder tumors. Value of monocyte activation in intravesical bacillus Calmette-Guérin therapy. Nissenkorn, I., Lavie, G., Keisari, Y., Leib, Z., Vilcovsky, E., Servadio, C., Shachter, H. Eur. Urol. (1987) [Pubmed]
  7. Accumulation of nuclear p53 and tumor progression in bladder cancer. Esrig, D., Elmajian, D., Groshen, S., Freeman, J.A., Stein, J.P., Chen, S.C., Nichols, P.W., Skinner, D.G., Jones, P.A., Cote, R.J. N. Engl. J. Med. (1994) [Pubmed]
  8. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. Pedersen-Bjergaard, J., Ersbøll, J., Hansen, V.L., Sørensen, B.L., Christoffersen, K., Hou-Jensen, K., Nissen, N.I., Knudsen, J.B., Hansen, M.M. N. Engl. J. Med. (1988) [Pubmed]
  9. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. Prout, G.R., Lin, C.W., Benson, R., Nseyo, U.O., Daly, J.J., Griffin, P.P., Kinsey, J., Tian, M.E., Lao, Y.H., Mian, Y.Z. N. Engl. J. Med. (1987) [Pubmed]
  10. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. Bugajska, U., Georgopoulos, N.T., Southgate, J., Johnson, P.W., Graber, P., Gordon, J., Selby, P.J., Trejdosiewicz, L.K. J. Natl. Cancer Inst. (2002) [Pubmed]
  11. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. Seligman, P.A., Crawford, E.D. J. Natl. Cancer Inst. (1991) [Pubmed]
  12. A quantitative dosing schedule for the induction of transitional cell carcinomas in female F344 rats with the use of N-butyl-N-(4-hydroxybutyl)nitrosamine. Becci, P.J., Thompson, H.J., Grubbs, C.J., Moon, R.C. J. Natl. Cancer Inst. (1979) [Pubmed]
  13. Alkaline phosphatase activity in hyperplastic and neoplastic urinary bladder epithelium of mice fed 2-acetylaminofluorene. Highman, B., Frith, C.H., Littlefield, N.A. J. Natl. Cancer Inst. (1975) [Pubmed]
  14. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. Bajorin, D.F., McCaffrey, J.A., Hilton, S., Mazumdar, M., Kelly, W.K., Scher, H.I., Spicer, J., Herr, H., Higgins, G. J. Clin. Oncol. (1998) [Pubmed]
  15. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. Hillcoat, B.L., Raghavan, D., Matthews, J., Kefford, R., Yuen, K., Woods, R., Olver, I., Bishop, J., Pearson, B., Coorey, G. J. Clin. Oncol. (1989) [Pubmed]
  16. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Theodorescu, D., Cornil, I., Fernandez, B.J., Kerbel, R.S. Proc. Natl. Acad. Sci. U.S.A. (1990) [Pubmed]
  17. Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Theodorescu, D., Cornil, I., Sheehan, C., Man, M.S., Kerbel, R.S. Cancer Res. (1991) [Pubmed]
  18. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. Dodd, P.M., McCaffrey, J.A., Hilton, S., Mazumdar, M., Herr, H., Kelly, W.K., Icasiano, E., Boyle, M.G., Bajorin, D.F. J. Clin. Oncol. (2000) [Pubmed]
  19. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Del Pizzo, J.J., Borkowski, A., Jacobs, S.C., Kyprianou, N. Am. J. Pathol. (1999) [Pubmed]
  20. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Sibley, K., Cuthbert-Heavens, D., Knowles, M.A. Oncogene (2001) [Pubmed]
  21. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. Harker, W.G., Meyers, F.J., Freiha, F.S., Palmer, J.M., Shortliffe, L.D., Hannigan, J.F., McWhirter, K.M., Torti, F.M. J. Clin. Oncol. (1985) [Pubmed]
  22. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. Li, J., Juliar, B., Yiannoutsos, C., Ansari, R., Fox, E., Fisch, M.J., Einhorn, L.H., Sweeney, C.J. J. Clin. Oncol. (2005) [Pubmed]
  23. Inhibitory effect of testosterone on gap junctional intercellular communication of human transitional cell carcinoma cell lines. Kihara, K., Fukui, I., Higashi, Y., Oshima, H. Cancer Res. (1990) [Pubmed]
  24. Initiation of urinary bladder carcinogenesis in rats by freeze ulceration with sodium saccharin promotion. Hasegawa, R., Greenfield, R.E., Murasaki, G., Suzuki, T., Cohen, S.M. Cancer Res. (1985) [Pubmed]
  25. Galactosyl transferase activity in human transitional cell carcinoma lines and in benign and neoplastic human bladder epithelium. Plotkin, G.M., Wides, R.J., Gilbert, S.L., Wolf, G., Hagen, I.K., Prout, G.R. Cancer Res. (1979) [Pubmed]
  26. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation. Lee, C.C., Yamamoto, S., Wanibuchi, H., Wada, S., Sugimura, K., Kishimoto, T., Fukushima, S. Cancer Res. (1997) [Pubmed]
  27. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Mohammed, S.I., Knapp, D.W., Bostwick, D.G., Foster, R.S., Khan, K.N., Masferrer, J.L., Woerner, B.M., Snyder, P.W., Koki, A.T. Cancer Res. (1999) [Pubmed]
  28. Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Matin, S.F., Rackley, R.R., Sadhukhan, P.C., Kim, M.S., Novick, A.C., Bandyopadhyay, S.K. Cancer Res. (2001) [Pubmed]
  29. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Amara, N., Palapattu, G.S., Schrage, M., Gu, Z., Thomas, G.V., Dorey, F., Said, J., Reiter, R.E. Cancer Res. (2001) [Pubmed]
  30. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Brown, L.F., Berse, B., Jackman, R.W., Tognazzi, K., Manseau, E.J., Dvorak, H.F., Senger, D.R. Am. J. Pathol. (1993) [Pubmed]
  31. Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report. Sternberg, J.J., Bracken, R.B., Handel, P.B., Johnson, D.E. JAMA (1977) [Pubmed]
  32. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. Meluch, A.A., Greco, F.A., Burris, H.A., O'Rourke, T., Ortega, G., Steis, R.G., Morrissey, L.H., Johnson, V., Hainsworth, J.D. J. Clin. Oncol. (2001) [Pubmed]
  33. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Lattime, E.C., Gomella, L.G., McCue, P.A. Cancer Res. (1992) [Pubmed]
  34. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Kurashige, T., Noguchi, Y., Saika, T., Ono, T., Nagata, Y., Jungbluth, A., Ritter, G., Chen, Y.T., Stockert, E., Tsushima, T., Kumon, H., Old, L.J., Nakayama, E. Cancer Res. (2001) [Pubmed]
WikiGenes - Universities